Value through Innovation20 October 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

17.07.2013

Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding

16.07.2013

Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure

- For media outside of the US, the UK & Canada only
16.07.2013

Healthrageous, United BioSource and Boehringer Ingelheim launch SMART digital diabetes Study

15.07.2013

U.S. FDA approves Gilotrif™ (afatinib)* as first-line treatment for lung cancer patients with EGFR mutations

- For non U.S. Media Only
10.07.2013

Boehringer Ingelheim and Ashoka Changemakers Announce Winners of Transforming Health Systems Competition

08.07.2013

Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product

25.06.2013

Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials presented at ADA

- For Non-U.S. and Non-UK media
24.06.2013

Application submitted to the European Medicines Agency (EMA) for use of Pradaxa® in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE

- For media outside of the U.S., the UK & Canada only
22.06.2013

Trajenta® (linagliptin): New data on safety and efficacy in Type 2 Diabetes patients with moderate to severe renal impairment

- For Non-U.S. and Non-UK media
22.06.2013

New efficacy and safety data presented for Trajenta® (linagliptin) in Asians with Type 2 Diabetes

- For Non-US and Non-UK Media
22.06.2013

Study finds investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes and impaired kidney function

- For Non-US and Non-UK Media
22.06.2013

Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin

- For Non-US and Non-UK Media
22.06.2013

Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulphonylurea in adults with Type 2 Diabetes

- For Non-US and Non-UK Media
22.06.2013

Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with Type 2 Diabetes

- For Non-US and Non-UK Media
17.06.2013

New long-term data reinforce safety profile of Pradaxa® for stroke prevention in AF

- For media outside of the US, the UK & Canada only
13.06.2013

Boehringer Ingelheim’s investigational all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C patients

- For media outside USA, UK and Canada only
11.06.2013

Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations in Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association® Scientific Sessions

- Ex US & UK Medical Media Only
08.06.2013

Boehringer Ingelheim’s investigational faldaprevir+ achieved viral cure in 88% of treatment-naïve hepatitis C patients in Asia

- For media outside USA, UK and Canada only